HmG- Human Menopausal Gonadotropin

Human Menopausal Gonadotropin (hMG) is a medication used in fertility treatments to stimulate ovulation in women who are unable to ovulate naturally. It contains two hormones: follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which are naturally produced by the pituitary gland in the brain. hMG is extracted from the urine of postmenopausal women and is a hormonally active medication that stimulates the growth and development of multiple ovarian follicles.

In Aashakiran IVF, hMG is commonly used in combination with other fertility drugs, such as gonadotropin-releasing hormone (GnRH) agonists or antagonists, to control the timing of ovulation and increase the chances of successful conception. The medication is typically given as a subcutaneous injection, which is administered daily for about 10-12 days. During this time, the woman's ovarian response is closely monitored using ultrasounds and blood tests to assess the number and size of follicles, and adjust the dosage of hMG if necessary.

hMG is often used in conjunction with other assisted reproductive technologies, such as intrauterine insemination (IUI) or in vitro fertilization (IVF). In IVF, hMG is given to stimulate the ovaries to produce multiple follicles, which are then retrieved and fertilized in a laboratory with sperm to create embryos. The resulting embryos are then transferred to the woman's uterus for implantation.

As with any medication, hMG may cause side effects such as headache, abdominal pain, bloating, and mood swings. In rare cases, it can also cause ovarian hyperstimulation syndrome (OHSS), a potentially serious condition in which the ovaries become swollen and painful. Close monitoring by a fertility specialist can help minimize these risks and ensure the safe and effective use of hMG.